Panel discussion on large cell lymphomas: subtypes, patient selection and mutations

Andrew Zelenetz, MD, PhD of Memorial Sloan Kettering Cancer Center, New York, NY talks about large cell lymphoma with Michael Pfreundschuh, MD of Saarland University, Saarbrücken, Germany, David Scott, MBChB, PhD of British Columbia Cancer Agency, Vancouver, BC and Laura Pasqualucci, MD of Columbia University Medical Center, New York, NY. Dr Scott starts by talking about the complexity underlying diffuse large B-cell lymphoma (DLBCL) and the subtypes, activated B-cell (ABC) type and germinal center (GC) DLBCL. Dr Pfreundschuh talks about the status of patient selection and cell of origin in large cell lymphoma clinical trials as well as NanoString technology in trials in the RICOVER-60 trial in elderly patients (NCT00052936) and the Mega-CHOEP trial in young high-risk patients (NCT00129090) and targeted therapy. Dr Pasqualucci talks about somatic mutations and genomic studies. They then discuss patient selection in clinical trials, trial design and epigenetic modifiers.
Recorded at the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) meeting held in San Diego, CA.

Share this video